Exploring the Interplay Between with the Expression of MicroRNA, and Inflammatory Mediators in Colorectal Cancer

Overview

Journal Front Microbiol

Specialty Microbiology

Date 2023 Dec 11

PMID 38075864

Authors

Narjess Bostanghadiri

Shabnam Razavi

Aref Shariati

Malihe Talebi

Shiva Mirkalantari

Amirnader Emami Razavi

Davood Darban-Sarokhalil

Affiliations

Soon will be listed here.

Abstract

Background: has been recognized as an important key bacterium in the cause and spread of colorectal carcinogenesis. Nevertheless, the clinical relevance of in colorectal cancer (CRC) and its effect on immune factors and the tumor microenvironment have not been fully elucidated.

Materials And Methods: The frequency of was measured in 100 paired tumor and normal tissue specimens by TaqMan quantification Real-Time Polymerase Chain Reaction (qPCR). The mRNA expression levels of cytokines (β, α, and ), and miRNAs () were examined. Eventually, any potential correlations between the molecular and clinicopathological features of the neoplastic samples and the abundance of were analyzed.

Results: The relative frequency of was significantly increased in cancerous tissue compared to adjacent non-tumor tissues. Furthermore, the high level of was significantly associated with histological grade III and IV CRC tissues ( = 0.027 and = 0.022, respectively) and perineural invasion-positive patients ( = 0.037). In addition, the expression levels of αβ, and as well as and showed a significant increase in the cancer group. A notable correlation was also observed between the high status of and the expression of α and .

Conclusion: Our results emphasize the importance of and changes in the expression of genes involved in CRC. Studying the microbial profile and gene expression changes in CRC patients may be a promising approach to improve screening methods and provide therapeutic strategies.

Citing Articles

Global prevalence of Fusobacterium nucleatum and Bacteroides fragilis in patients with colorectal cancer: an overview of case reports/case series and meta-analysis of prevalence studies.

Sameni F, Elkhichi P, Dadashi A, Sadeghi M, Goudarzi M, Eshkalak M BMC Gastroenterol. 2025; 25(1):71.

PMID: 39930345 PMC: 11808969. DOI: 10.1186/s12876-025-03664-x.

Fecal Microbiota Strongly Correlates with Tissue Microbiota Composition in Colorectal Cancer but Not in Non-Small Cell Lung Cancer.

Vicente-Valor J, Tesolato S, Paz-Cabezas M, Gomez-Garre D, Ortega-Hernandez A, de la Serna S Int J Mol Sci. 2025; 26(2).

PMID: 39859429 PMC: 11766298. DOI: 10.3390/ijms26020717.

Unveiling the hidden link between oral flora and colorectal cancer: a bidirectional Mendelian randomization analysis and meta-analysis.

Zhang Z, Wu W, Xiahou Z, Song Y Front Microbiol. 2024; 15:1451160.

PMID: 39318433 PMC: 11420047. DOI: 10.3389/fmicb.2024.1451160.

Oral microbiota and metabolites: key players in oral health and disorder, and microbiota-based therapies.

Bostanghadiri N, Kouhzad M, Taki E, Elahi Z, Khoshbayan A, Navidifar T Front Microbiol. 2024; 15:1431785.

PMID: 39228377 PMC: 11368800. DOI: 10.3389/fmicb.2024.1431785.

Antioxidant Role of Probiotics in Inflammation-Induced Colorectal Cancer.

Hamamah S, Lobiuc A, Covasa M Int J Mol Sci. 2024; 25(16).

PMID: 39201713 PMC: 11354872. DOI: 10.3390/ijms25169026.

References

de Carvalho A, Pereira L, Datorre J, Dos Santos W, Berardinelli G, Matsushita M . Microbiota Profile and Impact of in Colorectal Cancer Patients of Barretos Cancer Hospital. Front Oncol. 2019; 9:813. PMC: 6727361. DOI: 10.3389/fonc.2019.00813. View

Heikkila K, Harris R, Lowe G, Rumley A, Yarnell J, Gallacher J . Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control. 2008; 20(1):15-26. DOI: 10.1007/s10552-008-9212-z. View

Nishijima S, Suda W, Oshima K, Kim S, Hirose Y, Morita H . The gut microbiome of healthy Japanese and its microbial and functional uniqueness. DNA Res. 2016; 23(2):125-33. PMC: 4833420. DOI: 10.1093/dnares/dsw002. View

Kashani N, Bezmin Abadi A, Rahimi F, Forootan M . -positive is prevalent in biopsy specimens of Iranian patients with colorectal cancer. New Microbes New Infect. 2020; 34:100651. PMC: 6997561. DOI: 10.1016/j.nmni.2020.100651. View

Laurila E, Kallioniemi A . The diverse role of miR-31 in regulating cancer associated phenotypes. Genes Chromosomes Cancer. 2013; 52(12):1103-13. DOI: 10.1002/gcc.22107. View

Henstra C, van Praagh J, Olinga P, Nagelkerke A . The gastrointestinal microbiota in colorectal cancer cell migration and invasion. Clin Exp Metastasis. 2021; 38(6):495-510. DOI: 10.1007/s10585-021-10130-x. View

Sur D, Advani S, Braithwaite D . MicroRNA panels as diagnostic biomarkers for colorectal cancer: A systematic review and meta-analysis. Front Med (Lausanne). 2022; 9:915226. PMC: 9676370. DOI: 10.3389/fmed.2022.915226. View

Rye M, Garrett K, Holt R, Platell C, McCoy M . Fusobacterium nucleatum and Bacteroides fragilis detection in colorectal tumours: Optimal target site and correlation with total bacterial load. PLoS One. 2022; 17(1):e0262416. PMC: 8740967. DOI: 10.1371/journal.pone.0262416. View

Chen D, Wu J, Jin D, Wang B, Cao H . Fecal microbiota transplantation in cancer management: Current status and perspectives. Int J Cancer. 2018; 145(8):2021-2031. PMC: 6767494. DOI: 10.1002/ijc.32003. View

10.

McIlvanna E, Linden G, Craig S, Lundy F, James J . Fusobacterium nucleatum and oral cancer: a critical review. BMC Cancer. 2021; 21(1):1212. PMC: 8590362. DOI: 10.1186/s12885-021-08903-4. View

11.

Bustin S, Benes V, Garson J, Hellemans J, Huggett J, Kubista M . The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009; 55(4):611-22. DOI: 10.1373/clinchem.2008.112797. View

12.

Gerhard Rogler G, Haller D, Jobin C . Microbiota in chronic mucosal inflammation. Int J Inflam. 2011; 2010:395032. PMC: 3034944. DOI: 10.4061/2010/395032. View

13.

Rubinstein M, Wang X, Liu W, Hao Y, Cai G, Han Y . Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe. 2013; 14(2):195-206. PMC: 3770529. DOI: 10.1016/j.chom.2013.07.012. View

14.

Trinchieri G . Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003; 3(2):133-46. DOI: 10.1038/nri1001. View

15.

Betge J, Langner C . Vascular invasion, perineural invasion, and tumour budding: predictors of outcome in colorectal cancer. Acta Gastroenterol Belg. 2012; 74(4):516-29. View

16.

Leija-Martinez J, Del-Rio-Navarro B, Sanchez-Munoz F, Munoz-Hernandez O, Hong E, Giacoman-Martinez A . Associations of TNFA, IL17A, and RORC mRNA expression levels in peripheral blood leukocytes with obesity-related asthma in adolescents. Clin Immunol. 2021; 229:108715. DOI: 10.1016/j.clim.2021.108715. View

17.

Feng H, Ying R, Chai T, Chen H, Ju H . The association between IL-17 gene variants and risk of colorectal cancer in a Chinese population: A case-control study. Biosci Rep. 2019; 39(11). PMC: 6881208. DOI: 10.1042/BSR20190013. View

18.

Wei Z, Cao S, Liu S, Yao Z, Sun T, Li Y . Could gut microbiota serve as prognostic biomarker associated with colorectal cancer patients' survival? A pilot study on relevant mechanism. Oncotarget. 2016; 7(29):46158-46172. PMC: 5216788. DOI: 10.18632/oncotarget.10064. View

19.

Goradel N, Heidarzadeh S, Jahangiri S, Farhood B, Mortezaee K, Khanlarkhani N . Fusobacterium nucleatum and colorectal cancer: A mechanistic overview. J Cell Physiol. 2018; 234(3):2337-2344. DOI: 10.1002/jcp.27250. View

20.

Tran H, Thu T, Nguyen P, Vo C, Doan K, Minh C . Tumour microbiomes and Fusobacterium genomics in Vietnamese colorectal cancer patients. NPJ Biofilms Microbiomes. 2022; 8(1):87. PMC: 9616903. DOI: 10.1038/s41522-022-00351-7. View